Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Wins NY State Approval for NGS Pre-Implantation Genetic Screening

NEW YORK (GenomeWeb) – CombiMatrix said today that that the New York State Department of Health has approved its next-generation sequencing pre-implantation genetic screening test.

The company's CombiPGS test screens embryo biopsy cells for chromosomal abnormalities prior to implantation in women undergoing in vitro fertilization.

CombiMatrix introduced the new NGS version of the test this June, with the goal of transitioning all customers of its previous array-based PGS test to the newer sequencing version.

"CombiPGS by NGS is an important upgrade to our portfolio of reproductive health tests and we are pleased by the strong reception it has received from reproductive endocrinologist and IVF physicians who are key call points for this test," CombiMatrix President and CEO Mark McDonough said in a statement.

With this new approval, the company can now market the NGS version of the test in New York State, which McDonough said ranks second in the total number of IVF cycles performed nationally each year.


The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.